Sndromes neurolgicos paraneoplsicos (Parte I): Abordaje y caractersticas generales

Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: a retrospective multicentric cohort study. Sussman TA, Li H, Hobbs

Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study

Background: AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer.. Due

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small- cell lung cancer after disease progression on platinum-based therapy

Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncol- ogy

ANESTHESIOLOGY. LAHIRI BN, MILLAR F ET AL. ADVERSE EFFECTS OF LARGE TIDAL VOLUME AND LOW PEEP IN CANINE ACID ASPIRATION. GUINARD T, RAHN MB ET A L THE OPEN LUNG DURING SMALL

Specifically, ERK1/2 can participate in HuR phosphorylation, modifying its activity in a lung cancer cell line (Yang et al., 2004) or HuR cytoplasmic location in hepatic

[r]